Overview


According to FutureWise analysis the market for Amyotrophic Lateral Sclerosis Treatment is expected to register a CAGR of 6.00% from 2023-2031.

Amyotrophic Lateral Sclerosis, a condition also recognized as Lou Gehrig's disease, is an ailment that affects the motor neurons situated in the brain and spinal cord, causing gradual neurodegeneration. These motor neurons are responsible for transmitting signals from the brain to the muscles, enabling voluntary muscle movements. In ALS, the gradual deterioration and death of these motor neurons lead to muscle weakness, atrophy, and eventual paralysis. ALS typically manifests in adulthood, with symptoms often appearing between the ages of 40 and 70. 

Initial signs might include muscle twitching, weakness in the limbs, difficulty speaking or swallowing, and impaired motor coordination. As the disease progresses, patients may experience increasing difficulty with mobility, breathing, and other basic functions. Cognitive functions are typically spared in the majority of ALS cases, though a small percentage of patients might also experience changes in thinking and behavior. Unfortunately, a cure for ALS has not yet been discovered. Current treatment strategies primarily focus on managing symptoms, improving the quality of life, and providing comprehensive support to patients. This approach involves a combination of interventions such as medications like riluzole, which moderates neurotransmitter levels to slow down neuron damage. Physical, occupational, and speech therapies help maintain muscle function, enhance mobility, and address communication and swallowing difficulties. For breathing challenges, non-invasive or invasive ventilation methods may be employed. Nutritional support and assistive devices like wheelchairs and communication aids also play vital roles in patient care.

FutureWise Market Research has published a report that provides an insightful analysis of Amyotrophic Lateral Sclerosis Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Amyotrophic Lateral Sclerosis Treatment Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Corestem
  • AB Science
  • F.Hoffmann-La Roche AG
  • Biohaven Pharmaceutical
  • Sun Pharmaceutical
  • Ionis Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Amyotrophic Lateral Sclerosis Treatment Market:

  • In June 2022, the FDA authorized the marketing of Amylyx Pharmaceuticals Inc.'s groundbreaking drug ALBRIOZA (also known as AMX0035) for the treatment of amyotrophic lateral sclerosis in Canada.

The amyotrophic lateral sclerosis (ALS) treatment market is on a trajectory of growth, driven by several influential factors. The increasing prevalence of ALS and the expanding geriatric population are exerting a direct impact on the market's expansion. The United Nations World Population Prospects 2022 report reveals a substantial current population of 77.1 million individuals aged 65 and above, set to escalate to 1.6 billion by 2050. This surge in elderly demographics is anticipated to heighten the prevalence of rare neurological conditions, thereby propelling the ALS treatment market's growth during the forecast period. The ALS treatment market is also receiving a boost from technological advancements, augmented product approvals, and strategic partnerships. A notable example is the collaboration between CRISPR Therapeutics and CapsidaBiotherapeutics Inc., which seeks to develop innovative gene editing therapies using CRISPR technology. This alliance is anticipated to contribute to the market's growth trajectory. 

Despite the promising growth prospects in the amyotrophic lateral sclerosis (ALS) treatment market, several limitations are to be considered. High treatment costs could hinder accessibility for many individuals, while the limited number of treatment options may not cater to diverse patient needs. ALS's intricate and varied nature poses challenges in finding universally effective treatments, and the absence of early diagnostic tools delays intervention. Furthermore, available treatments offer modest efficacy, and public awareness about ALS remains relatively low, impacting research funding. Conducting clinical trials for ALS treatments is intricate due to the disease's rarity and progression variability. Treatment-related adverse effects and the lack of predictive biomarkers are also concerns. Ethical dilemmas regarding end-of-life care add to the complexity. Despite these limitations, ongoing research strives to overcome these challenges and enhance ALS understanding and management.

By Treatment

  • Medication
  • Stem Cell Therapy
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Due to factors such as increasing rare neurological diseases, a growing elderly population, robust industry presence, advanced healthcare infrastructure, rising tech awareness, and a concentration of market players in the United States, North America is poised to dominate the market. Government and healthcare organizations are taking steps to raise awareness about the disease and advance research and drug development. For example, in June 2022, the US FDA introduced an action plan for Rare Neurodegenerative Diseases, aimed at enhancing the lives of individuals affected by such conditions over a five-year span. This strategy focuses on developing safe medical products and ensuring access to innovative treatments. These initiatives are expected to bolster market growth in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Amyotrophic Lateral Sclerosis Treatment Market By Treatment, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Amyotrophic Lateral Sclerosis Treatment Market Variables, Trends and Scope
    •      1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Amyotrophic Lateral Sclerosis Treatment Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Amyotrophic Lateral Sclerosis Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Amyotrophic Lateral Sclerosis Treatment Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Medication
        2. Stem Cell Therapy
        3. Others

  • 8.   Amyotrophic Lateral Sclerosis Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others

  • 9.   North America Amyotrophic Lateral Sclerosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Mitsubishi Tanabe Pharma Corporation
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Otsuka Pharmaceutical Co., Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BrainStorm Therapeutics
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Biogen Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Corestem
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AB Science
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. F.Hoffmann-La Roche AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Biohaven Pharmaceutical
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sun Pharmaceutical
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Ionis Pharmaceuticals, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Multiple Sclerosis Drugs Market

Read More

Multiple Sclerosis Therapeutics Market

Read More

Systemic Sclerosis Treatment Market

Read More
Partner

Our Clients